PMID- 30524509
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220330
IS  - 1834-2612 (Print)
IS  - 1834-2612 (Electronic)
IS  - 1834-2612 (Linking)
VI  - 13
IP  - 3
DP  - 2018 Sep
TI  - Triple Smoking Cessation Therapy with Varenicline, Nicotine Patch and Nicotine 
      Lozenge: A Pilot Study to Assess Tolerability, Satisfaction, and End-of-Treatment 
      Quit Rates.
PG  - 145-153
LID - 10.1017/jsc.2017.18 [doi]
AB  - INTRODUCTION: The majority of attempts to stop smoking end in failure. One way to 
      improve success may be to explore different combinations of existing cessation 
      medications. AIMS: This observational study examined "triple therapy" 
      (varenicline + nicotine patch + nicotine lozenge) in 36 smokers trying to quit. 
      METHODS: A 12-week, observational study exploring tolerability, via adverse 
      events (AEs) elicited at each of 9 phone assessments. Secondary outcomes included 
      satisfaction rates, medication changes, and self-reported quit rates at week 12. 
      RESULTS: 35 of 36 participants reported at least one AE. Insomnia (75%), abnormal 
      dreams (72%) and nausea (64%) were most common. Most were mild to moderate. No 
      deaths, hospitalizations, cardiovascular events, or suicidality were reported. 
      Six participants (17%) decreased the dose of at least one medication, 5 (14%) 
      decreased the dose then discontinued at least one medication, and 13 (36%) 
      discontinued at least one medication without trying a lesser dose. Participants 
      were highly satisfied with their medications, and 58% reported quitting at 12 
      weeks, with 38% reporting prolonged abstinence. CONCLUSION: Despite high rates of 
      AEs and medication changes, high rates of satisfaction and self-reported 
      quitting, with no serious AEs, were observed with triple therapy. Additional data 
      on tolerability and efficacy are needed. TRIAL REGISTRATION: clinicaltrials.gov 
      number NCT02681510.
FAU - Berg, Kristin M
AU  - Berg KM
AD  - Division of General Internal Medicine, Department of Medicine, University of 
      Wisconsin School of Medicine and Public Health, 2828 Marshall Ct, Suite 100, 
      Madison, WI USA 53705.
AD  - Center for Tobacco Research and Intervention, University of Wisconsin School of 
      Medicine and Public Health, 1930 Monroe St, Suite 200, Madison, WI USA 53711.
AD  - Primary Care Research Fellowship, Department of Family Medicine and Community 
      Health, University of Wisconsin School of Medicine and Public Health, 1100 
      Delaplaine Ct, Madison, WI USA 53715.
FAU - Jorenby, Douglas E
AU  - Jorenby DE
AD  - Center for Tobacco Research and Intervention, University of Wisconsin School of 
      Medicine and Public Health, 1930 Monroe St, Suite 200, Madison, WI USA 53711.
FAU - Baker, Timothy B
AU  - Baker TB
AD  - Center for Tobacco Research and Intervention, University of Wisconsin School of 
      Medicine and Public Health, 1930 Monroe St, Suite 200, Madison, WI USA 53711.
FAU - Fiore, Michael C
AU  - Fiore MC
AD  - Center for Tobacco Research and Intervention, University of Wisconsin School of 
      Medicine and Public Health, 1930 Monroe St, Suite 200, Madison, WI USA 53711.
LA  - eng
SI  - ClinicalTrials.gov/NCT02681510
GR  - P01 CA180945/CA/NCI NIH HHS/United States
GR  - R35 CA197573/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20170925
PL  - England
TA  - J Smok Cessat
JT  - Journal of smoking cessation
JID - 101478447
PMC - PMC6277035
MID - NIHMS906353
COIS- Conflict of Interest Author KMB has no conflicts of interest, authors DEJ, TBB, 
      and MCF have no conflicts of interest although have received federal grants in 
      the past 3 years.
EDAT- 2018/12/14 06:00
MHDA- 2018/12/14 06:01
PMCR- 2019/09/01
CRDT- 2018/12/08 06:00
PHST- 2018/12/08 06:00 [entrez]
PHST- 2018/12/14 06:00 [pubmed]
PHST- 2018/12/14 06:01 [medline]
PHST- 2019/09/01 00:00 [pmc-release]
AID - 10.1017/jsc.2017.18 [doi]
PST - ppublish
SO  - J Smok Cessat. 2018 Sep;13(3):145-153. doi: 10.1017/jsc.2017.18. Epub 2017 Sep 
      25.